STOCK TITAN

Scribe Therapeutics: Andreessen reports 16.3% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Scribe Therapeutics, Inc. (SCTX) is the issuer covered by a Schedule 13G reporting beneficial ownership of its common stock as of September 30, 2026. AH Bio Fund II, L.P. reported 2,385,075 shares (12.6%), and AH Bio Fund III, L.P. reported 697,650 shares (3.7%); their respective general partners, AH Equity Partners Bio II, L.L.C. and AH Equity Partners Bio III, L.L.C., reported the same holdings.

Marc L. Andreessen and Benjamin A. Horowitz, managing members of both general partners, each reported shared voting and dispositive power over 3,082,725 shares (16.3%); neither reported sole voting or dispositive power. The shares are held directly by the funds, including as nominees for other named entities.

AH Bio Fund II beneficially owned shares 2,385,075 shares As of September 30, 2026
AH Bio Fund II ownership 12.6% As of September 30, 2026
AH Bio Fund III beneficially owned shares 697,650 shares As of September 30, 2026
AH Bio Fund III ownership 3.7% As of September 30, 2026
Shared voting and dispositive power reported by Marc L. Andreessen and Benjamin A. Horowitz 3,082,725 shares each Each reported 16.3% as of September 30, 2026
Shares outstanding 18,931,680 shares As of August 31, 2026; basis for the reported ownership percentages
beneficial ownership regulatory
"beneficial ownership of the Issuer's securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
sole voting power regulatory
"Sole Voting Power"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
shared voting power regulatory
"Shared Voting Power"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power"
as nominee technical
"as nominee for AH Bio Fund II-B, L.P."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SCTX shares did AH Bio Fund II report?

AH Bio Fund II reported beneficial ownership of 2,385,075 SCTX common shares as of September 30, 2026; its general partner, AH Equity Partners Bio II, L.L.C., reported the same amount.

How many SCTX shares did Marc L. Andreessen and Benjamin A. Horowitz report?

Marc L. Andreessen and Benjamin A. Horowitz each reported shared voting and dispositive power over 3,082,725 shares, equal to 16.3% of the class as of September 30, 2026. Neither reported sole voting or dispositive power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





811033109

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



AH Bio Fund II, L.P.
Signature:/s/ Phil Hathaway
Name/Title:By AH Equity Partners Bio II, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 1)
Date:11/16/2026
AH Equity Partners Bio II, L.L.C.
Signature:/s/ Phil Hathaway
Name/Title:By Phil Hathaway, Chief Operating Officer
Date:11/16/2026
AH Bio Fund III, L.P.
Signature:/s/ Phil Hathaway
Name/Title:By AH Equity Partners Bio III, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 2)
Date:11/16/2026
AH Equity Partners Bio III, L.L.C.
Signature:/s/ Phil Hathaway
Name/Title:By Phil Hathaway, Chief Operating Officer
Date:11/16/2026
Marc L. Andreessen
Signature:/s/ Phil Hathaway
Name/Title:By Phil Hathaway, Attorney-in-Fact
Date:11/16/2026
Benjamin A. Horowitz
Signature:/s/ Phil Hathaway
Name/Title:By Phil Hathaway, Attorney-in-Fact
Date:11/16/2026

Comments accompanying signature: Note 1: AH Bio Fund II, L.P. for itself and as nominee for AH Bio Fund II-B, L.P. Note 2: AH Bio Fund III, L.P. for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP.
Exhibit Information

Exhibit 24.1 Power of Attorney for Marc L. Andreessen, dated June 23, 2023. Exhibit 24.2 Power of Attorney for Benjamin A. Horowitz, dated June 22, 2023. Exhibit 99.1 Joint Filing Agreement

Keep reading